How do you approach front line treatment for TP53 mutated mantle cell lymphoma?
Since some prior studies (eg. Eskelund et al. Blood 2017 130:1903-10.) have shown intensive chemoimmunotherapy does not overcome the adverse prognosis associated with TP53 mutation, are novel or targeted therapies favored at this time?
Is ASCT +/- post-transplant maintenance therapy favored in young, fit patients?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · City of Hope
Answered on
For patients with TP53 mutations based on the information presented by Eskelund et al. and previous experience. Given the knowledge that the mutation is a dominant negative which eliminates and functional activity of the tumor suppressor it stands to reason that an durable response with chemotherapy...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · H Lee Moffitt Cancer Center
Answered on
Both R2 and I+R (or acala+R) are reasonable front-line approaches. Both approaches are tougher in those with proliferative bulky nodal disease (ki67>50%). We still can get responses, but is less common, and particularly for I+R, remissions tend to be shorter. If in this situation I would look at R2 ...
Join for free or sign in to see the full answer